Overview Dividends

(UHS) Universal Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9139031002

Hospitals, Outpatient, Behavioral, Insurance, Management

UHS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 32.63%
EPS Trend (3Y Correlation): 94.0%

UHS Revenue

Revenue Growth (3Y CAGR): 9.52%
Revenue Trend (3Y Correlation): 99.2%

Description: UHS Universal Health

Universal Health Services Inc (NYSE:UHS) is a healthcare conglomerate operating acute care hospitals, outpatient facilities, and behavioral health care centers. The companys diverse service offerings include general and specialty surgery, internal medicine, obstetrics, emergency care, radiology, oncology, and behavioral health services.

UHS generates revenue through two primary segments: Acute Care Hospital Services and Behavioral Health Care Services. The company also provides additional services such as commercial health insurance and various management services, including central purchasing, information services, and administrative personnel management.

To further analyze UHS, key performance indicators (KPIs) such as revenue growth, EBITDA margin, and occupancy rates can be examined. For instance, UHSs revenue growth can be evaluated against industry peers, while EBITDA margin can help assess the companys operational efficiency. Additionally, metrics like patient satisfaction scores, readmission rates, and average length of stay can provide insights into the quality of care and operational effectiveness.

From a financial perspective, UHSs return on equity (RoE) of 17.92% indicates a relatively strong ability to generate profits from shareholder equity. Furthermore, the companys price-to-earnings (P/E) ratio of 9.49 suggests that UHS may be undervalued compared to its earnings, potentially presenting an attractive investment opportunity. Other relevant KPIs, such as debt-to-equity ratio and interest coverage ratio, can help assess UHSs financial leverage and ability to meet its debt obligations.

UHS Stock Overview

Market Cap in USD	11,555m
Sub-Industry	Health Care Facilities
IPO / Inception	1990-03-26

UHS Stock Ratings

Growth Rating	24.6%
Fundamental	78.5%
Dividend Rating	34.7%
Return 12m vs S&P 500	-30.7%
Analyst Rating	3.79 of 5

UHS Dividends

Dividend Yield 12m	0.43%
Yield on Cost 5y	0.70%
Annual Growth 5y	31.95%
Payout Consistency	58.1%
Payout Ratio	4.3%

UHS Growth Ratios

Growth Correlation 3m	39.5%
Growth Correlation 12m	-66%
Growth Correlation 5y	68.1%
CAGR 5y	25.54%
CAGR/Max DD 3y	0.72
CAGR/Mean DD 3y	2.38
Sharpe Ratio 12m	0.82
Alpha	-35.52
Beta	0.974
Volatility	30.15%
Current Volume	736.6k
Average Volume 20d	675.4k
Stop Loss	185.9 (-3%)
Signal	1.04

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (1.26b TTM) > 0 and > 6% of Revenue (6% = 987.6m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 0.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 4.09% (prev 3.94%; Δ 0.15pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 1.90b > Net Income 1.26b (YES >=105%, WARN >=100%)

Net Debt (4.87b) to EBITDA (2.43b) ratio: 2.01 <= 3.0 (WARN <= 3.5)

Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (65.0m) change vs 12m ago -4.31% (target <= -2.0% for YES)

Gross Margin 90.17% (prev 89.58%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 113.3% (prev 106.7%; Δ 6.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 11.43 (EBITDA TTM 2.43b / Interest Expense TTM 160.1m) >= 6 (WARN >= 3)

Altman Z'' 3.86

(A) 0.04 = (Total Current Assets 2.99b - Total Current Liabilities 2.32b) / Total Assets 14.99b

(B) 0.51 = Retained Earnings (Balance) 7.71b / Total Assets 14.99b

(D) 0.99 = Book Value of Equity 7.77b / Total Liabilities 7.84b

Total Rating: 3.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 78.53

1. Piotroski 7.50pt = 2.50

2. FCF Yield 5.61% = 2.80

3. FCF Margin 5.48% = 1.37

4. Debt/Equity 0.66 = 2.29

5. Debt/Ebitda 1.92 = 0.16

6. ROIC - WACC 5.49% = 6.86

7. RoE 18.62% = 1.55

8. Rev. Trend 99.18% = 4.96

9. Rev. CAGR 9.52% = 1.19

10. EPS Trend 93.98% = 2.35

11. EPS CAGR 32.63% = 2.50

What is the price of UHS shares?

As of September 15, 2025, the stock is trading at USD 191.72 with a total of 736,600 shares traded.
Over the past week, the price has changed by +3.21%, over one month by +7.38%, over three months by +12.66% and over the past year by -18.06%.

Is Universal Health a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Universal Health (NYSE:UHS) is currently (September 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 78.53 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UHS is around 195.25 USD . This means that UHS is currently overvalued and has a potential downside of 1.84%.

Is UHS a buy, sell or hold?

Universal Health has received a consensus analysts rating of 3.79. Therefor, it is recommend to hold UHS.

Strong Buy: 7
Buy: 1
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the UHS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	218.3	13.9%
Analysts Target Price	218.3	13.9%
ValueRay Target Price	214.8	12%

Last update: 2025-09-05 05:05

UHS Fundamental Data Overview

Market Cap USD = 11.55b (11.55b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 137.6m USD (last quarter)
P/E Trailing = 9.5711
P/E Forward = 8.1301
P/S = 0.702
P/B = 1.6436
P/EG = 1.87
Beta = 1.281
Revenue TTM = 16.46b USD
EBIT TTM = 1.83b USD
EBITDA TTM = 2.43b USD
Long Term Debt = 4.54b USD (from longTermDebt, last quarter)
Short Term Debt = 114.1m USD (from shortTermDebt, last quarter)
Debt = 4.66b USD (Calculated: Short Term 114.1m + Long Term 4.54b)
Net Debt = 4.87b USD (from netDebt column, last quarter)
Enterprise Value = 16.07b USD (11.55b + Debt 4.66b - CCE 137.6m)
Interest Coverage Ratio = 11.43 (Ebit TTM 1.83b / Interest Expense TTM 160.1m)
FCF Yield = 5.61% (FCF TTM 901.5m / Enterprise Value 16.07b)
FCF Margin = 5.48% (FCF TTM 901.5m / Revenue TTM 16.46b)
Net Margin = 7.66% (Net Income TTM 1.26b / Revenue TTM 16.46b)
Gross Margin = 90.17% ((Revenue TTM 16.46b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Tobins Q-Ratio = 2.07 (Enterprise Value 16.07b / Book Value Of Equity 7.77b)
Interest Expense / Debt = 0.74% (Interest Expense 34.5m / Debt 4.66b)
Taxrate = 22.35% (334.8m / 1.50b)
NOPAT = 1.42b (EBIT 1.83b * (1 - 22.35%))
Current Ratio = 1.29 (Total Current Assets 2.99b / Total Current Liabilities 2.32b)
Debt / Equity = 0.66 (Debt 4.66b / last Quarter total Stockholder Equity 7.03b)
Debt / EBITDA = 1.92 (Net Debt 4.87b / EBITDA 2.43b)
Debt / FCF = 5.16 (Debt 4.66b / FCF TTM 901.5m)
Total Stockholder Equity = 6.77b (last 4 quarters mean)
RoA = 8.41% (Net Income 1.26b, Total Assets 14.99b )
RoE = 18.62% (Net Income TTM 1.26b / Total Stockholder Equity 6.77b)
RoCE = 16.17% (Ebit 1.83b / (Equity 6.77b + L.T.Debt 4.54b))
RoIC = 12.50% (NOPAT 1.42b / Invested Capital 11.37b)
WACC = 7.01% (E(11.55b)/V(16.21b) * Re(9.60%)) + (D(4.66b)/V(16.21b) * Rd(0.74%) * (1-Tc(0.22)))
Shares Correlation 3-Years: -96.97 | Cagr: -1.06%
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.55% ; FCFE base≈874.3m ; Y1≈1.08b ; Y5≈1.84b
Fair Price DCF = 420.7 (DCF Value 23.72b / Shares Outstanding 56.4m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 99.18 | Revenue CAGR: 9.52%
Rev Growth-of-Growth: 0.77
EPS Correlation: 93.98 | EPS CAGR: 32.63%
EPS Growth-of-Growth: 7.36

Additional Sources for UHS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle